Latest Product Development News

Lion Rock Minerals has revealed high-grade rare earth element mineralisation starting at surface at its Minta Project in Cameroon, with assays showing up to 21.15% TREO in saprolite and a magnet-rich rare earth basket. A large-scale drilling campaign is underway to further define this significant discovery.

Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.

TALi Digital (ASX:TD1) is raising up to $3.3 million through a Security Purchase Plan and Placement to fund its acquisition of Datasphere Analytics and advance its AI-driven education platform.

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

Cycliq Group Limited reported a 20.7% revenue decline to AUD 3.79 million for FY2026, but reduced its net loss by 83% to AUD 85,897, driven by disciplined cost control and strategic platform investments.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Eden Innovations Ltd trimmed its loss to $5 million in FY2026 while erasing bank debt and converting loans into equity, supported by property sales and capital raises.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Activeport Group Ltd’s FY26 results show a 36% revenue decline to $6.15 million and a net loss of $14.7 million, driven by strategic shifts towards recurring software revenue and AI infrastructure orchestration. The company launched its own national network in Australia and expanded internationally with new subsidiaries and leadership hires.

Advance ZincTek posted an 11% rise in FY26 profit before tax to $2.247 million on 12.6% higher sales, driven by AI integration and US market strength. The company is set to enter residential battery manufacturing in FY27, leveraging its zinc oxide expertise.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

The Calmer Co. International Limited posted a record $8.1 million revenue for FY26, driven by retail and wholesale growth, yet recorded a $3.8 million net loss amid ongoing funding challenges and strategic investments.